ARS Pharmaceuticals, Inc. Fair Value Adjustment of Warrants
ARS Pharmaceuticals, Inc. (SPRY) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-21.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2024-03-21
- ARS Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2023-09-30 was $0.00.
- ARS Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2023-06-30 was $0.00.
- ARS Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2023-03-31 was $0.00.
- ARS Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ARS Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2022 was $140.00K.
- ARS Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2021 was -$4.00K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 derived: sum of 2 quarters · filed 2024-03-21 | $0.00 derived: sum of 3 quarters · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $143.00K derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $143.00K derived: sum of 3 quarters · filed 2024-03-21 | $143.00K derived: sum of 4 quarters · filed 2024-03-21 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | $143.00K derived: sum of 2 quarters · filed 2024-03-21 | $143.00K derived: sum of 3 quarters · filed 2024-03-21 | $141.00K derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $143.00K derived: sum of 2 quarters · filed 2024-03-21 | $141.00K derived: sum of 3 quarters · filed 2024-03-21 | $140.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$2.00K derived: sum of 2 quarters · filed 2023-11-09 | -$3.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$3.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$1.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$4.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |